TransCon PTH for Hypoparathyroidism
(PaTH Forward Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests TransCon PTH, an injectable medication, on patients who might benefit from PTH treatment. It helps regulate calcium levels in the body, which is important for bone health and other functions. TransCon PTH is designed to overcome limitations of existing treatments.
Who Is on the Research Team?
Aimee Shu, MD
Principal Investigator
Ascendis Pharma A/S Medical Monitor/Medical Expert
Are You a Good Fit for This Trial?
Adults over 18 with chronic hypoparathyroidism (HP) for at least half a year, taking specific vitamin D and calcium supplements, can join this trial. They must be able to self-inject medication and not have certain genetic mutations or recent use of related drugs. Pregnant women, those with severe heart or kidney issues, drug/alcohol dependence, or other conditions affecting calcium metabolism are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomly assigned to receive either TransCon PTH or placebo for four weeks, administered as a subcutaneous injection using a pre-filled injection pen
Open-label extension
Participants receive open-label TransCon PTH with dose adjustments based on individual needs for up to 262 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Placebo for TransCon PTH
- TransCon PTH
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ascendis Pharma A/S
Lead Sponsor